Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Eisai Enters Global Agreement with Broad Institute of US to Develop New Drugs for NTDs and Tuberculosis
November 12, 2013
- 4 Major Wholesalers’ Operating Margins Stay on Recovery Path, But Average Settlement Rate at Mere 72% at Sept.-End
November 11, 2013
- Nichi-Iko Pres. Airs Frustration with Sanofi over Cancellation of Biosimlar Codevelopment Deal
November 8, 2013
- Nichi-Iko Pitting Allegra AG against Other Generics, Not Originator: Pres. Tamura
November 8, 2013
- Bristol-Myers Files NDA for DCV/ASV Combination Therapy for Treatment of Hepatitis C in Japan
November 8, 2013
- MTPC Aims to Reach Midterm Targets through Royalties from Licensed Products, But Success Likely to Depend on Performance in Domestic Market
November 8, 2013
- Japan ARB Market Gets Back on Growth Track in April-September; No Major Impact from Diovan Woes
November 6, 2013
- Safety Profile Holds Key to Triumph of Edoxaban: Daiichi Sankyo President
November 6, 2013
- Daiichi Sankyo President Apologizes Over Ranbaxy Problem, Pledges to Resolve Issue by Dispatching Employees
November 6, 2013
- Takeda to Cut Costs by 100 Billion Yen, Reduce Workforce by Below 5%
November 5, 2013
- Growth-Engine Drugs Jack Up Eisai Sales in April-September; Aricept’s Japan Target within Sight
November 5, 2013
- Astellas Plans to Tap 300 Workers in Japan for Early Retirement in FY2014
November 5, 2013
- Astellas 1st Half Operating Profit Down 4.4% on Higher Sales
November 5, 2013
- Shionogi Logs Record Profits in April-September on Rigid Cost Control
November 1, 2013
- Daiichi Sankyo Sales Up 7% Thanks to Nexium, Ranbaxy Posts Net Loss
November 1, 2013
- Takeda 1st Half Sales Rise 5.3% on New Portfolio, Weaker Yen
November 1, 2013
- MTPC Sales of Domestic Ethical Drugs Down 3.2% in April-September Period Due to Generic Competition
October 31, 2013
- DSP North America Sales Up 11.8% Due to Latuda, Japan Sales Down 4.2% in April-September Period
October 31, 2013
- Stock-Out of Mucosolate, Lemalc Due to Non-Conformance Results of Dissolution Testing, Stable Supply to Resume Next Spring: Teva Pharma Japan
October 31, 2013
- Teva Pharma Japan Notifies Customers of Stock-Out of Mucosolate L Cap.45, Lemalc Tab. 100 Due to Manufacturing Troubles
October 30, 2013
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…